Search Results
Your search for Susan Reckling,Susan Reckling matches 62 pages
Showing 1 - 50Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically
The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...
An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate
At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...
Promoting Cardiovascular Health in Adult Survivors of Childhood Cancers
Although more than 85% of childhood cancer survivors will achieve a 5-year survival,1 that does not tell the whole tale for these individuals who move into adulthood. They are at excess risk of late mortality, even 40 years out from a cancer diagnosis, from non–cancer-related causes,1 and related...
Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL
With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...
Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer
Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...
Relationship Between Second Malignant Neoplasm and Heart Disease Studied in Childhood Cancer Survivors
In a French study of more than 7,000 childhood cancer survivors, published in JACC: CardioOncology, Thibaud Charrier, PhD, of the Université Paris-Saclay, Villejuif, France, and colleagues reported that the occurrence of a second malignant neoplasm among these childhood cancer survivors seemed to...
International Collaborative Research Efforts in Cardio-Oncology
At the 2023 Global Cardio-Oncology Symposium (GCOS), international experts explored the ongoing collaborative efforts to improve the cardiovascular health of patients being treated for cancer as well as the bidirectional challenges of translating basic research to clinical care. Focus on Basic and...
Immune Checkpoint Inhibitor–Induced Myocarditis: Contemporary Retrospective Analysis
In a retrospective cohort study of 160 patients with cancer who were suspected of having immune checkpoint inhibitor (ICI)-induced myocarditis, published in JACC: CardioOncology, Osnat Itzhaki Ben Zadok, MD, MSc, and colleagues found that severe ICI-induced myocarditis seemed to be linked to...
International Collaborative Research Efforts in Cardio-oncology: Focus on Basic and Translational Science
Translational research is a key ingredient in guiding both genetic and pharmacologic cardioprotective approaches in patients being treated for cancer, according to international experts from the International Cardio-Oncology Society and the Global Cardio-Oncology Symposium (GCOS) committee. Fadi N. ...
Expert Point of View: Susan Faye Dent, MD
In a joint ASCO/ICOS (International Cardio-Oncology Society) session presented at the 2023 Global Cardio-Oncology Summit, Dr. Anita Arnold and Dr. Krishnan Bhaskaran discussed the importance of understanding the impact of cancer therapy on the cardiovascular health of women. Medical oncologist...
Cardiovascular Health of Women Treated for Cancer: Understanding the Long-Term Risks
At the 2023 Global Cardio-Oncology Summit in Madrid, in a joint session with ASCO and the International Cardio-Oncology Society, Anita Arnold, DO, FACC, MBA, Director, Noninvasive Cardiology, and Director of Cardio-Oncology, Lee Memorial Health Systems, Fort Myers, Florida, discussed the...
Childhood Cancer Survivors: Risk of Second Cancer and Heart Disease
In a French study of more than 7,000 childhood cancer survivors published by Charrier et al in JACC: CardioOncology, researchers reported that the occurrence of a second malignant neoplasm among these survivors seemed to be associated with an increased risk of cardiac disease occurrence and risk at ...
Cardiac Imaging and Biomarkers for Patients Receiving Cancer Treatment: What Oncologists Need to Know
For many years, researchers around the world have been exploring the connections between cancer treatments and the heart—better known as cardio-oncology. However, many oncologists may be less familiar with this emerging field and what they might need to know in terms of heart health to keep their...
Cardiovascular Disease and Cancer: A Reciprocal Relationship?
More attention is being paid to the topic of cardio-oncology, where the focus is on patients with cancer who may be at risk for developing cardiovascular diseases as a result of anticancer treatments. However, a less well-known but related clinical area is now garnering some interest. Referred to...
No Improvement in Survival with High-dose over Standard-dose Radiation for Stage III Non–Small Cell Lung Cancer
Surprisingly, less may be more when it comes to radiation therapy with concurrent chemotherapy for patients with stage III non–small cell lung cancer (NSCLC), according to an interim analysis of the randomized phase III Radiation Therapy Oncology Group (RTOG) 0617 trial presented at the 53rd Annual ...
Expert Point of View: Hypofractionated Radiotherapy Effectively Controls High-risk Prostate Cancer
The take-home message of the study findings from the Fox Chase trial reported at the 53rd ASTRO Annual Meeting plenary session supports the use of hypofractionated intensity-modulated radiotherapy as a more convenient and cost-effective alternative than conventional IMRT, according to formal...
Hypofractionated Radiotherapy Effectively Controls High-risk Prostate Cancer
The use of hypofractionated intensity-modulated radiotherapy (IMRT) appears to be a reasonable option for men with intermediate- to high-risk prostate cancer,1 reported Alan Pollack, MD, Chairman of Radiation Oncology at the University of Miami Miller School of Medicine in Miami and lead...
Despite Challenges, Combined-modality Therapy Warranted for Locally Recurrent Colorectal Cancer
Encouraging outcomes have been achieved with a combined-modality treatment approach for patients with locally recurrent colorectal cancer in both curative and palliative settings, although room for improvement remains. During a session presented at the American Society for Radiation Oncology...
Preoperative Chemoradiotherapy May Extend Survival for Patients with Esophagogastric Junction Adenocarcinoma
Several American and European clinical trials have yielded mixed results on the survival advantage of preoperative chemoradiotherapy for patients with locally advanced esophagogastric junction adenonocarcinoma. However, a distinguished panel at the 2011 ASTRO Annual Meeting did agree that surgery...
Expert Point of View: Fewer Rectal Side Effects with IMRT than with 3D-CRT for Prostate Cancer
Although the early toxicity findings of RTOG 0126 seem to favor IMRT over 3D-CRT, formal discussant of this trial, Juanita Crook, MD, FRCPC, of the British Columbia Cancer Agency, Kelowna, British Columbia, Canada, put the study’s findings in perspective. “Whether or not this is a significant...
Fewer Rectal Side Effects with IMRT than with 3D-CRT for Prostate Cancer
The use of intensity-modulated radiation therapy (IMRT) is associated with fewer acute and late toxic effects than is three-dimensional conformal radiation therapy (3D-CRT) in men with localized prostate cancer, according to preliminary analysis of the Radiation Therapy Oncology Group (RTOG) 0126...
SIDEBAR: Photodynamic Therapy for Cancer
Photodynamic therapy is a two-step treatment that includes a photosensitizing agent and a light source. In the first step, the photosensitizing agent (porfimer sodium) is injected into the bloodstream and absorbed by all cells. Over 24 to 48 hours, the drug is concentrated in cancer cells. In the...
International Photodynamic Medicine Symposium: Shedding New Light on an Old Therapy
This past May, a collaborative think tank of researchers was convened at The Ohio State University, Columbus, to share their expertise in a somewhat older treatment that is reemerging on many fronts: photodynamic therapy. Participants from the United States, Great Britain, and Japan took part in...
APSHO: New Society for Advanced Practitioners
The Advanced Practitioner Society for Hematology and Oncology (APSHO) was launched during JADPRO Live. The Society is focused on meeting the unique educational and professional needs of this group of health-care professionals (nurse practioners, physician assistants, clinical nurse specialists,...
Leaders of ASCO, ASH, ASTRO, and NCCN Embrace Collaboration With Advanced Practitioners
Nearly 250 advanced practitioners assembled at the first annual JADPRO Live educational symposium in St. Petersburg, Florida, hosted by the Journal of the Advanced Practitioner in Oncology (JADPRO). Leaders from four prominent oncology organizations championed collaborative practice as not only...
SIDEBAR: Meet the Panel
Laura Zitella, MS, RN, ACNP-BC, AOCN®, moderator: Lead Advanced Practice Provider, Inpatient Hematology/Oncology, Stanford University Medical Center, Stanford, California, and Clinical Assistant Professor, Department of Physiological Nursing, University of California, San Francisco Jeannine M....
Advanced Practitioners in Oncology: Diverse Experiences, Shared Challenges
The professional paths of advanced practitioners (APs) in oncology are as varied as the locations in which they work. The first annual JADPRO Live 2014 educational symposium was held in St. Petersburg, Florida, and hosted by JADPRO, the Journal of the Advanced Practitioner in Oncology. A...
The Affordable Care Act: NCCN Panelists Rate It ‘Average’
Oncologists and third-party payers are already experiencing changes as a result of the Affordable Care Act, which earned an “average” rating by a panel of providers, payers, and patients assembled at the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN) in Hollywood,...
2015 Review of Newly Approved Oncologic Therapies
Over the past year or so, a host of new agents were approved for the treatment of patients with various types of cancer (see related article on page 1). Patrick Medina, PharmD, of the University of Oklahoma College of Pharmacy, Oklahoma City, and Monique Giordana, PharmD, BCOP, of Regions...
Ovarian Cancer: Current Treatment and Patient Management
Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...
Pelvic Radiotherapy May Benefit Some Women With Ovarian Clear Cell Adenocarcinoma
Adjuvant radiotherapy may play a role in the management of ovarian clear cell adenocarcinoma, which appears to be less prone to peritoneal dissemination than other subtypes, according to the results of a small retrospective study reported by Macrie et al in the International Journal of...
Low Mitotic Count Is an Independent Predictor of Survival in Women With Recurrent Uterine Leiomyosarcoma
Although low mitotic count, surgery, and disease-free interval of more than 6 months were associated with improved survival in women with recurrent or persistent uterine leiomyosarcoma, only low number of mitoses was identified as an independent predictor of survival post relapse, according to...
Racial Differences in the Risk of Second Breast Tumors Reported in Women With Ductal Carcinoma in Situ
Regardless of age at diagnosis, type of treatment, tumor grade or size, and tumor histology, black and Hispanic women had a higher risk of second ipsilateral breast tumors than did white women after ductal carcinoma in situ, according to the results of a large registry study presented by Liu et al...
Sex Steroid Hormones May Play a Role in the Development of Aggressive Prostate Cancer
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
Study Finds Association Between Increased Esophageal COX-2 Expression and Barrett’s Esophagus, Obesity, and Smoking
Elevated esophageal mucosa cyclooxygenase-2 (COX-2) levels appear to be associated with the presence of Barrett’s esophagus as well as high waist-to-hip ratios and current tobacco smoking, according to the results of a study reported by Nguyen et al in Digestive Diseases & Sciences. These ...
Pilot Study Evaluates Concurrent Use of Sunitinib and Radiation Therapy in Recurrent High-Grade Glioma
The combination of continuous daily-dosed sunitinib (Sutent) and hypofractionated stereotactic radiation therapy produced acceptable toxicity and “encouraging” 6-month progression-free survival in previously irradiated patients with recurrent high-grade glioma, according to the results...
mTOR Inhibitor Ridaforolimus Shows Activity in Advanced Endometrial Cancer
The oral mTOR inhibitor ridaforolimus was modestly active and reasonably tolerated in women with recurrent or metastatic endometrial cancer, according to the results of a phase II study reported in Gynecologic Oncology. Tsoref et al suggested that it may prove to be an effective therapeutic...
Patients With Peritoneal Hepatocellular Carcinoma May Benefit From Cytoreductive Surgery With or Without Intraperitoneal Chemotherapy
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy extended survival over systemic therapy alone in well-selected candidates with peritoneal hepatocellular carcinoma, according to the results of a small retrospective trial reported by Tabrizian et al in the Journal of...
More Accurate Identification of Molecular Subgroups May Better Guide Neoadjuvant Treatment of Breast Cancer
BluePrint in combination with MammaPrint molecular subtyping reclassified more than 20% of breast cancer patients into a different subgroup compared with conventional assessment, according to the results of the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST). In Annals of Surgical...
Adults With Exclusively Pulmonary Metastases From Ewing Sarcoma May Benefit From Whole-Lung Irradiation
Nearly half of adult patients with lung-only metastases from Ewing sarcoma who received whole-lung irradiation were free of pulmonary relapse at 3 years, according to the results of a retrospective study in the International Journal of Radiation Oncology • Biology • Physics. With few...
Improved Overall Survival With Primary Over Consolidation Intraperitoneal Chemotherapy After Optimal Cytoreduction for Advanced Ovarian Cancer
Compared with intravenous (IV) followed by consolidation intraperitoneal (IP) chemotherapy, primary IV/IP chemotherapy was associated with a statistically significant improvement in overall survival—but not progression-free survival—in patients with advanced epithelial ovarian cancer...
First Surveillance Imaging at 6 Months May Be Adequate for Most Patients After Treatment for Early-Stage Non‒Small Cell Lung Cancer
Early surveillance imaging (< 6 months) after stereotactic body radiation therapy for early-stage non–small cell lung cancer (NSCLC) seems to be of limited benefit, resulting in definitive intervention in only 3% of patients, according to the findings of a study in Practical Radiation...
Noninvasive Image Texture Analysis May Provide Tumor Heterogeneity Information With Prognostic Potential in NSCLC
Noninvasive quantitative computed tomography–based texture analysis can accurately differentiate the presence of a KRAS mutation from pan–wild-type non–small cell lung cancer (NSCLC), based on the results of a study in PLOS ONE. Weiss et al reported that this tumor heterogeneity...
Preclinical Study Reveals Heparan Sulfate Suppresses Growth of Neuroblastoma
A heparin derivative differentiated cancer cells and caused neuroblastomas to regress without causing severe bleeding, according to the findings of a preclinical study presented in The Journal of Clinical Investigation. Knelson et al identified novel roles for heparan sulfate proteoglycans in...
Similar Survival Rates, Less Toxicity Reported With Reduced-Intensity vs Myeloablative Total-Body Irradiation Before Transplant in Acute Leukemia
Used as a conditioning regimen for allogeneic transplantation in patients with acute leukemia, reduced-intensity total-body irradiation yielded similar overall and relapse-free survival rates to those seen with myeloablative total-body irradiation but with shorter hospital stays and fewer intensive ...
Study Reveals Long-Term Benefits With Prone Hypofractionated Radiation Therapy and a Concurrent Boost in Early-Stage Breast Cancer
Prone accelerated intensity-modulated radiation therapy with a concomitant boost produced excellent local tumor control and cosmesis while sparing normal tissues in women with early-stage breast cancer, according to the 5-year study results reported by Osa et al in the International Journal of...
Palliative Resection of Primary Tumor May Improve Survival in Patients With Metastatic Colorectal Cancer
Palliative resection of the primary tumor was associated with a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic colorectal cancer, according to the results of a study reported in the Annals of Surgical Oncology. Gresham et al noted...
Initial Treatment of Ductal Carcinoma in Situ May Affect Subsequent Treatment of Tumor Recurrences After Surgery
The use of radiotherapy for the index ductal carcinoma in situ (DCIS) may affect subsequent treatment of tumor recurrences and complications after breast-conserving surgery, reported Greenberg et al in the Annals of Surgical Oncology. Based on the results of this retrospective cohort study, the...
Proactive Patient-Centered Program May Reduce the Risk of Lymphedema in Survivors of Breast Cancer
A patient-centered educational and behavioral program focusing on self-care strategies appears to be an effective way to reduce the risk of lymphedema in survivors of breast cancer, according to the results of a prospective study by Fu et al at New York University. These findings, reported in the...
